| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | -100.0% |
| Cost of Revenue | $0 | — | -100.0% |
| R&D Expense | $14.3M | -70.6% | +43.5% |
| SG&A Expense | $5.2M | -12.4% | -27.6% |
| Operating Income | -$19.5M | +64.3% | -45.7% |
| Income Tax | $0 | — | — |
| Net Income | -$17.7M | +66.3% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $37.9M | -73.8% | +24.2% |
| Short-term Investments | $124.7M | +286.4% | +288.6% |
| Accounts Receivable | $0 | — | -100.0% |
| Inventory | $0 | — | -100.0% |
| Current Assets | $165.0M | -7.6% | +113.5% |
| Total Assets | $167.0M |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$80.2M | — | — |
| Capital Expenditures | $552K | — | — |
| Investing Cash Flow | -$5.0M | — | — |
| Financing Cash Flow | $94.4M | — | — |
| Free Cash Flow | -$80.8M | — | — |
| -41.4% |
| EPS (Basic) | -$0.26 | +65.8% | +43.5% |
| EPS (Diluted) | -$0.26 | +65.8% | +43.5% |
| -7.6% |
| +94.9% |
| Current Liabilities | $9.8M | +12.5% | -37.7% |
| Total Liabilities | $9.8M | +12.5% | -41.5% |
| Stockholders' Equity | $157.2M | -8.7% | +128.2% |